Pliant Therapeutics (PLRX) Q4 2025 earnings summary

Executive summary

• Achieved deep and durable responses in Phase 1 trial of PLN-101095 for ICI-refractory solid tumors, leading to an accelerated development plan and initiation of a Phase 1b expansion trial.

• Expanded clinical-stage pipeline leveraging integrin-based therapeutics and advanced integrin-targeted delivery platform for siRNA payloads.

• Appointed Minnie Kuo as Chief Operating Officer to oversee clinical operations and regulatory affairs.

Financial highlights

• Research and development expenses decreased to $15.6M from $38.8M year-over-year, mainly due to discontinuation of BEACON-IPF.

• General and administrative expenses fell to $8.0M from $14.5M year-over-year, reflecting workforce restructuring.

• Net loss narrowed to $23.6M from $49.7M year-over-year for the quarter.

• Cash, cash equivalents, and short-term investments totaled $192.4M as of December 31, 2025, expected to fund operations into the second half of 2028.

• Net loss per share for the quarter was $0.38, compared to $0.82 in the prior-year quarter.

Outlook and guidance

• First patient enrollment for the Phase 1b PLN-101095 trial anticipated in Q2 2026, with interim data expected in 2027.

• Cash runway projected to last into the second half of 2028.